Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Conditions
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
Interventions
YL201, Atezolizumab
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Plantation, Florida • Louisville, Kentucky + 2 more
Conditions
Advanced Solid Tumors
Interventions
YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
11
States / cities
Aurora, Colorado • Denver, Colorado • North Haven, Connecticut + 7 more
Conditions
Non Small Cell Lung Cancer, Breast Cancer
Interventions
YL202
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Plantation, Florida • Detroit, Michigan • Houston, Texas + 4 more
Conditions
Advanced Solid Tumors
Interventions
intravenous (IV) infusion
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
11
States / cities
Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 8 more
Conditions
Non-small Cell Lung Cancer
Interventions
BNT326, Pumitamig
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
11
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 8 more
Conditions
Advanced Solid Tumor
Interventions
YL217, Bevacizumab, 5-FU with leucovorin
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
12
States / cities
Phoenix, Arizona • Santa Monica, California • New Haven, Connecticut + 9 more
Conditions
Advanced Solid Tumor
Interventions
YL201, YL201 and atezolizumab
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Fair Oaks, California • La Jolla, California • Lone Tree, Colorado + 16 more
Conditions
Advanced Solid Tumor
Interventions
YL242, YL242; Pembrolizumab, YL242; 5-FU; LV, YL242; Pembrolizumab; 5-FU
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
New Haven, Connecticut • Sarasota, Florida • Boston, Massachusetts + 4 more